| Accelerated hypertension | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Aneurysm | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Angiodysplasia | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Aortic aneurysm | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG00112 affected6,452 at risk
|
| Aortic aneurysm rupture | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Aortic dissection | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Aortic occlusion | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Aortic stenosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Aortic thrombosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Arterial disorder | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Arterial haemorrhage | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Arterial insufficiency | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Arterial occlusive disease | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Arterial thrombosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Arteriosclerosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Arteriovenous fistula | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Circulatory collapse | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Coeliac artery occlusion | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Deep vein thrombosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG00112 affected6,452 at risk
|
| Diabetic microangiopathy | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Embolism | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Extremity necrosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Femoral artery aneurysm | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Femoral artery dissection | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Femoral artery occlusion | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Haematoma | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Haemodynamic instability | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Haemorrhage | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypertension | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00038 affected6,465 at risk
- EG00115 affected6,452 at risk
|
| Hypertensive crisis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00019 affected6,465 at risk
- EG00113 affected6,452 at risk
|
| Hypertensive emergency | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypotension | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00025 affected6,465 at risk
- EG00118 affected6,452 at risk
|
| Hypovolaemic shock | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Iliac artery occlusion | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Iliac artery rupture | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Intermittent claudication | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00017 affected6,465 at risk
- EG00115 affected6,452 at risk
|
| Ischaemic limb pain | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Jugular vein thrombosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Leriche syndrome | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lymphatic fistula | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lymphocele | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Malignant hypertension | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Orthostatic hypotension | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Peripheral arterial occlusive disease | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00039 affected6,465 at risk
- EG00136 affected6,452 at risk
|
| Peripheral artery aneurysm | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Peripheral artery dissection | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Peripheral artery stenosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00015 affected6,465 at risk
- EG00125 affected6,452 at risk
|
| Peripheral artery thrombosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Peripheral embolism | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Peripheral ischaemia | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00015 affected6,465 at risk
- EG00117 affected6,452 at risk
|
| Peripheral vascular disorder | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG00015 affected6,465 at risk
- EG00113 affected6,452 at risk
|
| Polyarteritis nodosa | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Post thrombotic syndrome | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Reperfusion injury | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Shock haemorrhagic | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Subclavian artery stenosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Temporal arteritis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Thrombophlebitis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Thrombophlebitis superficial | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Varicose vein | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Vascular insufficiency | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vascular occlusion | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vascular pain | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vascular stenosis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vasculitis | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Venous thrombosis limb | Vascular disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Coronary angioplasty | Surgical and medical procedures | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Coronary artery bypass | Surgical and medical procedures | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Percutaneous coronary intervention | Surgical and medical procedures | MedDRA 16.1 | Systematic Assessment | | - EG000252 affected6,465 at risk
- EG001262 affected6,452 at risk
|
| Acute leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Acute myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Acute promyelocytic leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Adenocarcinoma gastric | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Adenocarcinoma of colon | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Adenocarcinoma pancreas | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Adenoma benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Adenosquamous cell lung cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Anal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Angiocentric lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Angiosarcoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| B-cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| B-cell lymphoma recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Benign anorectal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Benign breast neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Benign gastric neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Benign gastrointestinal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Benign laryngeal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Benign lung neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Benign neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Benign neoplasm of adrenal gland | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Benign neoplasm of bladder | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Benign neoplasm of prostate | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Bile duct cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG00015 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Bladder cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Bladder cancer stage 0, with cancer in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bladder neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bladder papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bladder transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bone giant cell tumour benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Borderline ovarian tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Brain neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Breast cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Central nervous system neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cerebellar tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cervix carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cholangiocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Choroid melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Chronic lymphocytic leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Chronic myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Clear cell renal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Colon adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG00112 affected6,452 at risk
|
| Colon cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Colorectal adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cystadenocarcinoma ovary | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Desmoplastic melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Diffuse large B-cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Endometrial cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Essential thrombocythaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Fibroma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Gastric cancer stage I | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastric neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastrointestinal cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastrointestinal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Gastrointestinal stromal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastrointestinal stromal tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastrointestinal tract adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Glioblastoma multiforme | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Glottis carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Haemangioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Haemangioma of liver | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatic cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hepatocellular carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Large cell lung cancer stage IV | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Large intestine benign neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Laryngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Laryngeal squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Leiomyosarcoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lip neoplasm malignant stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lip squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lipoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lung adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG00112 affected6,452 at risk
|
| Lung carcinoma cell type unspecified recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lung neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG00111 affected6,452 at risk
|
| Lung squamous cell carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lung squamous cell carcinoma stage I | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Malignant neoplasm of ampulla of Vater | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Malignant neoplasm of unknown primary site | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Malignant neoplasm progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Melanoma recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Meningioma benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Mesothelioma malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastases to bone | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Metastases to central nervous system | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Metastases to liver | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Metastases to lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Metastases to lymph nodes | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastases to peritoneum | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Metastases to pleura | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastases to spine | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Metastatic bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastatic gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastatic lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastatic malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastatic neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Metastatic renal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Metastatic squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Metastatic uterine cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Myelodysplastic syndrome | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Myeloproliferative disorder | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Neurilemmoma benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Neuroendocrine carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Neuroendocrine carcinoma of the skin | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Neuroendocrine tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Non-small cell lung cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Non-small cell lung cancer stage IIIB | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Non-small cell lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Non-small cell lung cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Oesophageal adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Oesophageal cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Oesophageal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Oral cavity cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Oropharyngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Osteosarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ovarian cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ovarian cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ovarian germ cell teratoma benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pancreatic carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Paraneoplastic syndrome | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Paraproteinaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Plasma cell myeloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Plasmacytoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pleomorphic adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Polycythaemia vera | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Precursor B-lymphoblastic lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG00021 affected6,465 at risk
- EG00125 affected6,452 at risk
|
| Prostate cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Prostate cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Prostatic adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Rectal adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Rectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Rectal cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Rectosigmoid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Renal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Renal cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Renal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Renal cell carcinoma stage II | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Renal oncocytoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Sarcoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Signet-ring cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Skin cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Small cell lung cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Small cell lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Small intestine adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Squamous cell carcinoma of lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Squamous cell carcinoma of skin | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Squamous cell carcinoma of the tongue | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| T-cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Testis cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Thymoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Thyroid cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Tongue cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Tongue carcinoma stage IV | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Tongue neoplasm malignant stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Tonsil cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Tracheal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Transitional cell carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Uterine cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Vaginal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Allergy to arthropod bite | Immune system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Allergy to arthropod sting | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Anaphylactic reaction | Immune system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Anaphylactic shock | Immune system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Drug hypersensitivity | Immune system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Hypersensitivity | Immune system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Sarcoidosis | Immune system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Asthenia | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Cardiac death | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Chest discomfort | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Chest pain | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG00015 affected6,465 at risk
- EG00120 affected6,452 at risk
|
| Death | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG00036 affected6,465 at risk
- EG00134 affected6,452 at risk
|
| Device dislocation | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Device malfunction | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Device occlusion | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG00127 affected6,452 at risk
|
| Drug withdrawal syndrome | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Face oedema | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Fatigue | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gait disturbance | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| General physical health deterioration | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hernia obstructive | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hypothermia | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Impaired healing | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Inflammation | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Influenza like illness | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Local swelling | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Malaise | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Medical device complication | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Mucosal haemorrhage | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Multi-organ failure | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Nodule | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Non-cardiac chest pain | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG000298 affected6,465 at risk
- EG001248 affected6,452 at risk
|
| Oedema peripheral | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Pain | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Patient-device incompatibility | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pelvic mass | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Polyserositis | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pseudopolyp | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Puncture site haemorrhage | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pyrexia | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Stent malfunction | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Stent-graft endoleak | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Sudden cardiac death | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG00035 affected6,465 at risk
- EG00126 affected6,452 at risk
|
| Sudden death | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG00028 affected6,465 at risk
- EG00126 affected6,452 at risk
|
| Surgical failure | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Systemic inflammatory response syndrome | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Thrombosis in device | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Ulcer haemorrhage | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vessel puncture site thrombosis | General disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Abnormal behaviour | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Affective disorder | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Alcohol abuse | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Alcohol withdrawal syndrome | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Alcoholism | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Anxiety | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Anxiety disorder | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Bipolar I disorder | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Bipolar disorder | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Completed suicide | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Confusional state | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Delirium | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Depression | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Depression suicidal | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Disorientation | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Drug abuse | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Emotional distress | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Insomnia | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Major depression | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Mental disorder due to a general medical condition | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Mental status changes | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Mood disorder due to a general medical condition | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Psychotic disorder due to a general medical condition | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Schizophrenia, undifferentiated type | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Substance abuse | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Suicidal ideation | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Suicide attempt | Psychiatric disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Acquired phimosis | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Balanoposthitis | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG00012 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Breast pain | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cervical dysplasia | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cervix disorder | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cystocele | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Endometrial hyperplasia | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Epididymitis | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Erectile dysfunction | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Menometrorrhagia | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Organic erectile dysfunction | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ovarian cyst | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Perineal fistula | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Prostatic disorder | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Prostatism | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Prostatitis | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Rectocele | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Sperm granuloma | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Spermatocele | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Uterine polyp | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Uterine prolapse | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Uterovaginal prolapse | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vaginal haemorrhage | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Accidental overdose | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Afferent loop syndrome | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Alcohol poisoning | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Anaemia postoperative | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Anastomotic ulcer | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Arterial restenosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Arthropod sting | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Brain contusion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Burns second degree | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Burns third degree | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cardiac function disturbance postoperative | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cardiac procedure complication | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Carotid artery restenosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cerebral hyperperfusion syndrome | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cervical vertebral fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Chest injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Clavicle fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Comminuted fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Compression fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Concussion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Contrast media reaction | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Contusion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Coronary artery reocclusion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Coronary artery restenosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG00030 affected6,465 at risk
- EG00130 affected6,452 at risk
|
| Craniocerebral injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cystitis radiation | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Dural tear | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Electric shock | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Excoriation | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Exposure via inhalation | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Eye penetration | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Facial bones fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Fall | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Fat embolism | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Femoral neck fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Femur fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Fibula fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Foot fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Foreign body | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Fractured ischium | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastrointestinal disorder postoperative | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastrointestinal injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Graft thrombosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Gun shot wound | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Hand fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Head injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Heart injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Heat exhaustion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Heat stroke | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hip fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG00111 affected6,452 at risk
|
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Incision site pain | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Incisional hernia | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Intentional overdose | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Intestinal anastomosis complication | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Jaw fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Joint injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Kidney contusion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Laceration | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Ligament rupture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ligament sprain | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Limb injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lower limb fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Lumbar vertebral fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Meniscus injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Mountain sickness acute | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Multiple fractures | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Multiple injuries | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Muscle rupture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Muscle strain | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Overdose | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Pelvic fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Peroneal nerve injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pneumoconiosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Post procedural complication | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Post procedural contusion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Post procedural fistula | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Post procedural haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Post procedural myocardial infarction | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Post-traumatic pain | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Postoperative ileus | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Postoperative wound complication | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Postpericardiotomy syndrome | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Procedural complication | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Procedural haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Procedural headache | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pseudomeningocele | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pubis fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pulmonary contusion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Radius fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Renal haematoma | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Rib fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Scapula fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Scrotal haematoma | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Seroma | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Shunt stenosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Shunt thrombosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Skull fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Skull fractured base | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Spinal column injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Spinal compression fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Spinal fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Splenic injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Sternal fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Subcutaneous haematoma | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Subdural haematoma | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Subdural haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Tendon injury | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Tendon rupture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Tibia fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Toxicity to various agents | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Traumatic intracranial haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Traumatic shock | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Traumatic ulcer | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Upper limb fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vascular graft complication | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Vascular graft occlusion | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vascular graft thrombosis0 | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vascular procedure complication | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Vascular pseudoaneurysm | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Wound | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Wound dehiscence | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Wound necrosis | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Wrist fracture | Injury, poisoning and procedural complications | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Alanine aminotransferase increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Ammonia increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Aspartate aminotransferase increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Blood bilirubin increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Blood creatinine increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Blood glucose increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Blood potassium decreased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Blood potassium increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| C-reactive protein increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Cardiac enzymes increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cardiac output decreased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cardiac stress test abnormal | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Clostridium test positive | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| ECG signs of myocardial ischaemia | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ejection fraction decreased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Electrocardiogram QT prolonged | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Electrocardiogram ST segment depression | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Electrocardiogram ST segment elevation | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Exercise test abnormal | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Fibrin D dimer increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haemoglobin decreased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Heart rate increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatic enzyme abnormal | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatic enzyme increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| International normalised ratio increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Laboratory test abnormal | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Liver function test abnormal | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Platelet count increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pulmonary function test decreased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Transaminases increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Troponin I increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Troponin T increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Troponin increased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG00016 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Weight decreased | Investigations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Acute coronary syndrome | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG00111 affected6,452 at risk
|
| Acute left ventricular failure | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Acute myocardial infarction | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG000446 affected6,465 at risk
- EG001432 affected6,452 at risk
|
| Angina pectoris | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG000272 affected6,465 at risk
- EG001266 affected6,452 at risk
|
| Angina unstable | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG000546 affected6,465 at risk
- EG001562 affected6,452 at risk
|
| Aortic valve incompetence | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Aortic valve stenosis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Arrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Arrhythmia supraventricular | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Arteriosclerosis coronary artery | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG00111 affected6,452 at risk
|
| Arteriospasm coronary | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Atrial fibrillation | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG000108 affected6,465 at risk
- EG00176 affected6,452 at risk
|
| Atrial flutter | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG00113 affected6,452 at risk
|
| Atrial tachycardia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Atrial thrombosis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Atrioventricular block | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Atrioventricular block complete | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Atrioventricular block first degree | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Atrioventricular block second degree | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Bradyarrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Bradycardia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG00121 affected6,452 at risk
|
| Bundle branch block left | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cardiac aneurysm | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cardiac arrest | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00018 affected6,465 at risk
- EG00129 affected6,452 at risk
|
| Cardiac asthma | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Cardiac discomfort | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Cardiac failure | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG000176 affected6,465 at risk
- EG001170 affected6,452 at risk
|
| Cardiac failure acute | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00021 affected6,465 at risk
- EG00120 affected6,452 at risk
|
| Cardiac failure chronic | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG00116 affected6,452 at risk
|
| Cardiac failure congestive | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG000101 affected6,465 at risk
- EG001107 affected6,452 at risk
|
| Cardiac tamponade | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cardio-respiratory arrest | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Cardiogenic shock | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Cardiomyopathy | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Cardiopulmonary failure | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cardiorenal syndrome | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Cardiovascular disorder | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Cardiovascular insufficiency | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Chronotropic incompetence | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Conduction disorder | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Coronary artery disease | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG000145 affected6,465 at risk
- EG001139 affected6,452 at risk
|
| Coronary artery dissection | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Coronary artery insufficiency | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Coronary artery occlusion | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Coronary artery perforation | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Coronary artery stenosis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00059 affected6,465 at risk
- EG00138 affected6,452 at risk
|
| Coronary artery thrombosis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Dilatation ventricular | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypertensive heart disease | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Interventricular septum rupture | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Intracardiac thrombus | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Ischaemic cardiomyopathy | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Left ventricular dysfunction | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Left ventricular failure | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Microvascular coronary artery disease | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Mitral valve disease | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Mitral valve incompetence | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Myocardial fibrosis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Myocardial infarction | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00061 affected6,465 at risk
- EG00145 affected6,452 at risk
|
| Myocardial ischaemia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00053 affected6,465 at risk
- EG00147 affected6,452 at risk
|
| Myocardial rupture | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Myopericarditis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Nodal rhythm | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Palpitations | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Paroxysmal arrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pericardial effusion | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pericardial haemorrhage | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pericarditis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00012 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Pleuropericarditis | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Postinfarction angina | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Prinzmetal angina | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Pulseless electrical activity | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Restrictive cardiomyopathy | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Sick sinus syndrome | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Sinoatrial block | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Sinus arrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Sinus bradycardia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Sinus tachycardia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Stress cardiomyopathy | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Supraventricular extrasystoles | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Supraventricular tachyarrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Supraventricular tachycardia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Tachyarrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Tachycardia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Tachycardia paroxysmal | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Torsade de pointes | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Trifascicular block | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ventricle rupture | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ventricular arrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Ventricular dyssynchrony | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ventricular extrasystoles | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Ventricular fibrillation | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00014 affected6,465 at risk
- EG00112 affected6,452 at risk
|
| Ventricular tachyarrhythmia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ventricular tachycardia | Cardiac disorders | MedDRA 16.1 | Systematic Assessment | | - EG00028 affected6,465 at risk
- EG00119 affected6,452 at risk
|
| Atrial septal defect | Congenital, familial and genetic disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastrointestinal arteriovenous malformation | Congenital, familial and genetic disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Odontogenic cyst | Congenital, familial and genetic disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Phimosis | Congenital, familial and genetic disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Acute pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00016 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Acute respiratory distress syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Alveolitis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Asthma late onset | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bronchiectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bronchitis chronic | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Bronchospasm | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00045 affected6,465 at risk
- EG00156 affected6,452 at risk
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00027 affected6,465 at risk
- EG00121 affected6,452 at risk
|
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Dyspnoea paroxysmal nocturnal | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Emphysema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00013 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Granulomatous pneumonitis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haemothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Hydrothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Interstitial lung disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Laryngeal oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lung disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lung infiltration | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Nasal septum deviation | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Obstructive airways disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG00114 affected6,452 at risk
|
| Pleurisy | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Pleuritic pain | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pulmonary congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00022 affected6,465 at risk
- EG00128 affected6,452 at risk
|
| Pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pulmonary haemorrhage | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pulmonary mass | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00018 affected6,465 at risk
- EG00115 affected6,452 at risk
|
| Pulmonary sarcoidosis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pulmonary thrombosis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Respiratory arrest | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Respiratory depression | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Respiratory disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG00111 affected6,452 at risk
|
| Sleep apnoea syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Sputum retention | Respiratory, thoracic and mediastinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Agranulocytosis | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Anaemia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00043 affected6,465 at risk
- EG00149 affected6,452 at risk
|
| Anaemia macrocytic | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Aplastic anaemia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Coagulopathy | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haemorrhagic anaemia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Heparin-induced thrombocytopenia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hypercoagulation | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Leukocytosis | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lymphadenopathy mediastinal | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lymphoid tissue hyperplasia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Microcytic anaemia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Neutropenia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Normochromic normocytic anaemia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pancytopenia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Splenic infarction | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Aphasia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ataxia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Basilar migraine | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Brain injury | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Brain oedema | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Brain stem stroke | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Carotid arteriosclerosis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Carotid artery disease | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Carotid artery occlusion | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Carotid artery stenosis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00034 affected6,465 at risk
- EG00127 affected6,452 at risk
|
| Carotid sinus syndrome | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Carpal tunnel syndrome | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cerebellar ataxia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cerebellar haemorrhage | Blood and lymphatic system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cerebellar infarction | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cerebral arteriosclerosis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cerebral artery embolism | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cerebral circulatory failure | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cerebral haemorrhage | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Cerebral infarction | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Cerebral ischaemia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Cerebrovascular accident | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00016 affected6,465 at risk
- EG00119 affected6,452 at risk
|
| Cerebrovascular disorder | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cerebrovascular insufficiency | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cervical myelopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cervical neuritis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cervical radiculopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cervicobrachial syndrome | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Cognitive disorder | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Coma | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Complex regional pain syndrome | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Convulsion | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Dementia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Dementia Alzheimer's type | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Diabetic neuropathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Dizziness | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG00113 affected6,452 at risk
|
| Dysaesthesia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Dysarthria | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Embolic stroke | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Encephalopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Epilepsy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Frontotemporal dementia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Grand mal convulsion | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Haemorrhage intracranial | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Haemorrhagic cerebral infarction | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Haemorrhagic stroke | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Haemorrhagic transformation stroke | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Head discomfort | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Headache | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Hemiparesis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hemiplegia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hemiplegic migraine | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hyperaesthesia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hypoaesthesia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Hypoglycaemic coma | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypoglycaemic seizure | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypotonia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypoxic-ischaemic encephalopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Intercostal neuralgia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Intracranial aneurysm | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Intracranial haematoma | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ischaemic cerebral infarction | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG00114 affected6,452 at risk
|
| Ischaemic stroke | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00086 affected6,465 at risk
- EG00193 affected6,452 at risk
|
| Lacunar infarction | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Lethargy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Loss of consciousness | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lumbar radiculopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Migraine | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Monoparesis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Monoplegia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Motor neurone disease | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Multiple sclerosis relapse | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Narcolepsy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Neuralgia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Neuroglycopenia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Neuropathy peripheral | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Normal pressure hydrocephalus | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Occipital neuralgia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Paraesthesia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Paraplegia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Paresis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Parkinson's disease | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Peripheral sensory neuropathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Postictal paralysis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Presyncope | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00012 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Radiculopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Sciatica | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Sensory disturbance | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Simple partial seizures | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Speech disorder | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Spinal epidural haematoma | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Spondylitic myelopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Status epilepticus | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Subarachnoid haemorrhage | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Syncope | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00060 affected6,465 at risk
- EG00158 affected6,452 at risk
|
| Thalamic infarction | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Transient global amnesia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Transient ischaemic attack | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG00045 affected6,465 at risk
- EG00148 affected6,452 at risk
|
| Trigeminal neuralgia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| VIIth nerve paralysis | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vascular encephalopathy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vertebral artery occlusion | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vertebrobasilar insufficiency | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vertigo CNS origin | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Accommodation disorder | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Age-related macular degeneration | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Amaurosis fugax | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Blindness | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Blindness unilateral | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cataract | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG00112 affected6,452 at risk
|
| Cataract nuclear | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Diabetic retinopathy | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Diplopia | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ectropion | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Eye haemorrhage | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Eyelid cyst | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Glaucoma | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lens dislocation | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Macular hole | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Open angle glaucoma | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Optic neuropathy | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Retinal artery occlusion | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Retinal detachment | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Retinal haemorrhage | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Retinoschisis | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Visual acuity reduced | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Visual impairment | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vitreous haemorrhage | Eye disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Deafness | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Deafness neurosensory | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ear haemorrhage | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hearing impaired | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Sudden hearing loss | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Tinnitus | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vertigo | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Vertigo positional | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Vestibular disorder | Ear and labyrinth disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Abdominal adhesions | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Abdominal discomfort | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Abdominal distension | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Abdominal hernia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00012 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Abdominal pain lower | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Abdominal strangulated hernia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Abdominal wall haematoma | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Abnormal faeces | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Alcoholic pancreatitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Anal fissure | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Anal fistula | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Barrett's oesophagus | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Brunner's gland hyperplasia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Caecitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Coeliac artery stenosis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Colitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Colitis ischaemic | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Colitis ulcerative | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Colonic pseudo-obstruction | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Constipation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Crohn's disease | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Diabetic gastroparesis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Diaphragmatic hernia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG00114 affected6,452 at risk
|
| Diverticular perforation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Diverticulum | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Diverticulum intestinal | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Diverticulum intestinal haemorrhagic | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Duodenal polyp | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Duodenal ulcer | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Duodenal ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Duodenitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Duodenogastric reflux | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Dysphagia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Enteritis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Enterocele | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Enterocolitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Enterovesical fistula | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Erosive oesophagitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Faeces discoloured | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Femoral hernia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Food poisoning | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastric disorder | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Gastric haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Gastric perforation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastric polyps | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastric ulcer | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00017 affected6,465 at risk
- EG00113 affected6,452 at risk
|
| Gastric ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Gastritis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00016 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Gastritis atrophic | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastritis erosive | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Gastritis haemorrhagic | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastroduodenal ulcer | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastroduodenitis haemorrhagic | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastrointestinal disorder | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00026 affected6,465 at risk
- EG00118 affected6,452 at risk
|
| Gastrointestinal pain | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00013 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Gastrooesophagitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haematemesis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Haematochezia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haemorrhagic erosive gastritis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haemorrhoidal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Hiatus hernia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Hyperchlorhydria | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ileal perforation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ileal stenosis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ileus | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Ileus paralytic | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Inguinal hernia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00017 affected6,465 at risk
- EG00116 affected6,452 at risk
|
| Inguinal hernia, obstructive | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Intestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Intestinal infarction | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Intestinal ischaemia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Intestinal obstruction | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Intestinal perforation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Intestinal ulcer | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Intra-abdominal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Irritable bowel syndrome | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Large intestinal obstruction | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Large intestinal ulcer | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Large intestine perforation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Large intestine polyp | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Lower gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Mallory-Weiss syndrome | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Megacolon | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Melaena | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Mesenteric artery thrombosis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Mesenteric vein thrombosis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Nausea | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Obstruction gastric | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Odynophagia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Oesophageal disorder | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Oesophageal stenosis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Oesophageal ulcer | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Oesophagitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pancreatic disorder | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pancreatic pseudocyst | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pancreatitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Pancreatitis acute | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG00112 affected6,452 at risk
|
| Pancreatitis chronic | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pancreatitis relapsing | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Peptic ulcer | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Peptic ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Peptic ulcer perforation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Periproctitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Peritoneal adhesions | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Peritoneal mesothelial hyperplasia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pneumoperitoneum | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Proctitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Radicular cyst | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Rectal fissure | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Rectal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Rectal polyp | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Rectal ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Reflux gastritis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Retroperitoneal haematoma | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Retroperitoneal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Short-bowel syndrome | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Small intestinal obstruction | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Small intestinal perforation | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Small intestine polyp | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Stomatitis | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Subileus | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Umbilical hernia | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Umbilical hernia, obstructive | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Upper gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Uraemic gastropathy | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Varices oesophageal | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Vomiting | Gastrointestinal disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Metrorrhagia | Reproductive system and breast disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Acute prerenal failure | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Azotaemia | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bladder outlet obstruction | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bladder stenosis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Calculus bladder | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Calculus ureteric | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Calculus urethral | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Calculus urinary | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Cystitis haemorrhagic | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Diabetic nephropathy | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Haematuria | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG00013 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Haemorrhage urinary tract | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Hydronephrosis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypertensive nephropathy | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Micturition disorder | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Nephritis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Nephropathy | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Nephrotic syndrome | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Polyuria | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Renal artery arteriosclerosis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Renal artery occlusion | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Renal artery stenosis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Renal colic | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Renal failure | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG00019 affected6,465 at risk
- EG00120 affected6,452 at risk
|
| Renal failure acute | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG00046 affected6,465 at risk
- EG00144 affected6,452 at risk
|
| Renal failure chronic | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG00116 affected6,452 at risk
|
| Renal haemorrhage | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Renal hypertension | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Renal impairment | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Renal infarct | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Renal tubular necrosis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Stress urinary incontinence | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ureteric dilatation | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ureteric haemorrhage | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urethral haemorrhage | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urethral stenosis | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urinary bladder haemorrhage | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urinary bladder polyp | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urinary retention | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Urinoma | Renal and urinary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Acute hepatic failure | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Alcoholic liver disease | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Autoimmune hepatitis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Bile duct obstruction | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Bile duct stenosis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Bile duct stone | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Biliary colic | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Biliary dyskinesia | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cholangitis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Cholangitis acute | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cholecystitis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG00013 affected6,465 at risk
- EG00110 affected6,452 at risk
|
| Cholecystitis acute | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG00015 affected6,465 at risk
- EG00115 affected6,452 at risk
|
| Cholecystitis chronic | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cholelithiasis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG00018 affected6,465 at risk
- EG00123 affected6,452 at risk
|
| Cholestasis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Drug-induced liver injury | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Hepatic cirrhosis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatic cyst | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatic failure | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Hepatic function abnormal | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Hepatitis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hepatitis acute | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatitis alcoholic | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatitis cholestatic | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hepatitis toxic | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hepatocellular injury | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatorenal syndrome | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatotoxicity | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Ischaemic hepatitis | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Jaundice cholestatic | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Liver injury | Hepatobiliary disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Angioedema | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Decubitus ulcer | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Dermatitis allergic | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Diabetic foot | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Diabetic ulcer | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Dry gangrene | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Haemorrhage subcutaneous | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pemphigus | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Photosensitivity reaction | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Psoriasis | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Rash maculo-papular | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Rosacea | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Skin erosion | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Skin ulcer | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Stasis dermatitis | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Toxic skin eruption | Skin and subcutaneous tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Ankylosing spondylitis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Arthropathy | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0018 affected6,452 at risk
|
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cervical spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Compartment syndrome | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Costochondritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Fistula | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Flank pain | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Foot deformity | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Fracture malunion | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Fracture nonunion | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gouty arthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Intervertebral disc degeneration | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Intervertebral disc disorder | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Joint instability | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Limb discomfort | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Muscle disorder | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Muscle haemorrhage | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG00021 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Myositis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG00040 affected6,465 at risk
- EG00129 affected6,452 at risk
|
| Osteochondritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Osteochondrosis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Osteonecrosis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Osteoporosis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Pain in jaw | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Plantar fascial fibromatosis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Polyarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Polymyalgia rheumatica | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Polymyositis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Psoriatic arthropathy | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Rheumatoid arthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Rotator cuff syndrome | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Sensation of heaviness | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Sjogren's syndrome | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Spinal column stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Spinal osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Spinal pain | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Spondyloarthropathy | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Spondylolisthesis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Spondylolysis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Sympathetic posterior cervical syndrome | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Synovial cyst | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Synovitis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Tendonitis | Musculoskeletal and connective tissue disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Adrenal insufficiency | Endocrine disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Autoimmune thyroiditis | Endocrine disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Goitre | Endocrine disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Hyperthyroidism | Endocrine disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypothyroidism | Endocrine disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Primary hypothyroidism | Endocrine disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Dehydration | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG00018 affected6,465 at risk
- EG00119 affected6,452 at risk
|
| Diabetes mellitus inadequate control | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG00019 affected6,465 at risk
- EG00117 affected6,452 at risk
|
| Diabetic ketoacidosis | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Electrolyte imbalance | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Failure to thrive | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Fluid retention | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gout | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hydraemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypercalcaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Hyperlipidaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG00011 affected6,465 at risk
- EG00113 affected6,452 at risk
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Hypophagia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hypovolaemia | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Insulin-requiring type 2 diabetes mellitus | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Malnutrition | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Metabolic acidosis | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Type 2 diabetes mellitus | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG00021 affected6,465 at risk
- EG00121 affected6,452 at risk
|
| Abdominal abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Abdominal infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Abdominal wall abscess | Metabolism and nutrition disorders | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Abscess intestinal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Abscess limb | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Acarodermatitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Acute tonsillitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Anal abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Appendiceal abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Appendicitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Appendicitis perforated | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Arthritis bacterial | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Arthritis infective | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Bacteraemia | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Bacterial prostatitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bone abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Bronchitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG00019 affected6,465 at risk
- EG00129 affected6,452 at risk
|
| Bronchopneumonia | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG00010 affected6,465 at risk
- EG0019 affected6,452 at risk
|
| Burkholderia pseudomallei infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Bursitis infective | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Campylobacter infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cellulitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG00024 affected6,465 at risk
- EG00127 affected6,452 at risk
|
| Cellulitis staphylococcal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Cholangitis suppurative | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cholecystitis infective | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Chronic sinusitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Clostridium difficile colitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Clostridium difficile infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0007 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Creutzfeldt-Jakob disease | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cystitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Cytomegalovirus infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Device related infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Device related sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Diabetic foot infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Diabetic gangrene | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Diarrhoea infectious | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Diverticulitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG00016 affected6,465 at risk
- EG00114 affected6,452 at risk
|
| Eczema infected | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Empyema | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Endocarditis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Endocarditis enterococcal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Enteritis infectious | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Enterocolitis infectious | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Erysipelas | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Escherichia urinary tract infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gallbladder abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gallbladder empyema | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gangrene | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0008 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Gastric infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Gastroenteritis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG00020 affected6,465 at risk
- EG00118 affected6,452 at risk
|
| Gastroenteritis clostridial | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastroenteritis norovirus | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Gastroenteritis viral | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Gastrointestinal infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Graft infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Groin abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Groin infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Haematoma infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Helicobacter infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatitis C | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Hepatitis E | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Hepatitis infectious mononucleosis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Herpes zoster | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Impetigo | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Infected dermal cyst | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Infected lymphocele | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Infected skin ulcer | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Infective exacerbation of chronic obstructive airways disease | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Influenza | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Klebsiella infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Klebsiella sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Labyrinthitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Liver abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lobar pneumonia | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Localised infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Lower respiratory tract infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0014 affected6,452 at risk
|
| Lung abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Lung infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Lymphangitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Malaria | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Mastoiditis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Mediastinitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Meningitis tuberculous | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Necrotising fasciitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Neuroborreliosis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Oesophageal candidiasis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Orchitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Osteomyelitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Osteomyelitis acute | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Osteomyelitis chronic | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Otitis media | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pelvic abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pericarditis tuberculous | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Peritoneal abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Peritonitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Peritonsillar abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pharyngitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pneumococcal sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pneumonia | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG000113 affected6,465 at risk
- EG001130 affected6,452 at risk
|
| Pneumonia bacterial | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pneumonia fungal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Pneumonia influenzal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pneumonia pseudomonas aeruginosa | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pneumonia staphylococcal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pneumonia streptococcal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pneumonia viral | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Post procedural infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Post procedural pneumonia | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Post procedural sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Postoperative abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Postoperative wound infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Pseudomembranous colitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pseudomonas infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pulmonary sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pulmonary tuberculosis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pyelonephritis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Pyelonephritis acute | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Pyoderma streptococcal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Renal abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Respiratory tract infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Respiratory tract infection viral | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Respiratory tract infection bacterial | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Salmonellosis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Scrotal abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG00023 affected6,465 at risk
- EG00124 affected6,452 at risk
|
| Septic shock | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0009 affected6,465 at risk
- EG0016 affected6,452 at risk
|
| Sinusitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Skin bacterial infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Skin infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Staphylococcal abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Staphylococcal bacteraemia | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Staphylococcal infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0013 affected6,452 at risk
|
| Staphylococcal sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0003 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Staphylococcal skin infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Streptococcal bacteraemia | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Streptococcal sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Subcutaneous abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Superinfection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Testicular abscess | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Tonsillitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Tracheitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Tracheobronchitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Upper respiratory tract infection bacterial | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urinary tract infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG00047 affected6,465 at risk
- EG00125 affected6,452 at risk
|
| Urinary tract infection bacterial | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Urinary tract infection enterococcal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urinary tract infection pseudomonal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0010 affected6,452 at risk
|
| Urosepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0006 affected6,465 at risk
- EG0017 affected6,452 at risk
|
| Vestibular neuronitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0002 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Viral infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0004 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Viral upper respiratory tract infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Wound infection | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0005 affected6,465 at risk
- EG0015 affected6,452 at risk
|
| Wound infection pseudomonas | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Wound infection staphylococcal | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Wound sepsis | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0012 affected6,452 at risk
|
| Pneumonia legionella | Infections and infestations | MedDRA 16.1 | Systematic Assessment | | - EG0000 affected6,465 at risk
- EG0011 affected6,452 at risk
|
| Cerebellar haemorrhage | Nervous system disorders | MedDRA 16.1 | Systematic Assessment | | - EG0001 affected6,465 at risk
- EG0011 affected6,452 at risk
|